Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.6%
0%
14.6%
6 Months
-59.75%
0%
-59.75%
1 Year
-84.08%
0%
-84.08%
2 Years
-77.81%
0%
-77.81%
3 Years
121.34%
0%
121.34%
4 Years
-87.84%
0%
-87.84%
5 Years
-86.02%
0%
-86.02%
Myomo, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.17%
EBIT Growth (5y)
3.76%
EBIT to Interest (avg)
-9.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
1.84
Tax Ratio
7.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
63.52%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.94
EV to EBIT
-14.81
EV to EBITDA
-18.39
EV to Capital Employed
86.46
EV to Sales
2.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-583.82%
ROE (Latest)
-26.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 10 Schemes (6.31%)
Foreign Institutions
Held by 24 Foreign Institutions (10.76%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
9.70
9.80
-1.02%
Operating Profit (PBDIT) excl Other Income
-4.20
-3.10
-35.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.60
-3.50
-31.43%
Operating Profit Margin (Excl OI)
-475.60%
-358.00%
-11.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.02% vs -19.01% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -31.43% vs -1,066.67% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
32.60
19.20
69.79%
Operating Profit (PBDIT) excl Other Income
-5.40
-7.70
29.87%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.20
-8.10
23.46%
Operating Profit Margin (Excl OI)
-190.70%
-427.80%
23.71%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 69.79% vs 23.08% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 23.46% vs 24.30% in Dec 2023
About Myomo, Inc. 
Myomo, Inc.
Retailing
Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.
Company Coordinates 
Company Details
ONE BROADWAY, 14TH FLOOR , CAMBRIDGE MA : 02142
Registrar Details






